Status:
UNKNOWN
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
Lead Sponsor:
St. Bartholomew's Hospital
Conditions:
Graft Versus Host Disease
Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
RATIONALE: Studying ways to diagnose fungal infections early may help doctors plan the best treatment. PURPOSE: This clinical trial is studying laboratory tests to see how well they find aspergillosi...
Detailed Description
OBJECTIVES: Primary * Determine the test characteristics of galactomannan (GM) ELISA using serum and bronchoalveolar lavage fluid (BALF) collected from patients at high risk of invasive fungal infec...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- At high risk for developing invasive aspergillosis (IA) due to any of the following risk factors:
- Diagnosis of acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia AND meets ≥ 1 of the following criteria:
- Receiving intensive chemotherapy with expected duration of neutropenia (ANC \< 500/mm³) of \> 10 days
- Receiving high-dose steroids
- Concurrent treatment with allogeneic hematopoietic stem cell transplantation (HSCT)
- Requirement for high-dose steroids for graft-versus-host disease after HSCT
- History of probable or proven IA and receiving chemotherapy
- No preexisting chest disease
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00462657
Start Date
July 1 2005
Last Update
August 26 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Bartholomew's Hospital
London, England, United Kingdom, EC1A 7BE
2
Royal Brompton Hospital
London, England, United Kingdom, SW3 6NP